Viatris Q1 FY26: where the revenue came from and where it went
The income statement of Viatris for this quarter, down to the operating result, as one diagram: what earned the revenue and what it went on. The bottom line is withheld; the note under the table says why.
- Period
- Jan 1 – Mar 31, 2026
- Reported
- May 7, 2026
Revenue$3.52B
+8% year over year
Gross profit$1.16B
33% margin
Operating profit−$0.08B
−2% margin
The numbers
| Item | Value | Share of revenue | Year over year |
|---|---|---|---|
| Revenue | 3.52 | 100% | +8% |
| Brands | 2.33 | 66% | +10% |
| Lipitor | 0.46 | 13% | +19% |
| Other revenue | 0.27 | 8% | |
| Lyrica | 0.12 | 3% | +7% |
| Creon | 0.10 | 3% | +18% |
| Viagra | 0.10 | 3% | |
| Zoloft | 0.07 | 2% | +21% |
| Celebrex | 0.07 | 2% | |
| Cost of revenue | −2.36 | 67% | |
| Gross profit | 1.16 | 33% margin | −3pp |
| R&D | −0.25 | 7% | +0pp |
| SG&A | −0.93 | 26% | −3pp |
| Other | −0.06 | 2% | +0pp |
| Operating profit | −0.08 | −2% margin | +86pp |
95 of 418 companies, most recently reported first
New results in your inbox
When a big company reports, we send you a link to its diagram before anyone has time to comment on it. This is a mailing list, not an account: it does not open the diagrams by itself. No spam, one-click unsubscribe.
Drag or use the arrow keys to see the rest